(Q45858505)

17 December 2017

title

Should gene therapy be used for newborns with hemophilia? (English)

1 reference

17 December 2017

0 references

0 references

Katherine Parker Ponder

series ordinal

1

1 reference

17 December 2017

publication date

1 January 2003

1 reference

17 December 2017

published in

Molecular Therapy

1 reference

17 December 2017

volume

7

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

7-8

1 reference

17 December 2017

Gene therapy for hemophilia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Gene therapy: reality or myth for the global bleeding disorders community?

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Management of hemophilia in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Progress in haemophilic care: ethical issues

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Haemophilia care in the developing world: benchmarking for excellence

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Immunologic tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Correlation between factor VIII genotype and inhibitor development in hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Inhibitor antibodies to factor VIII and factor IX: management

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Clinical research. Gene therapy a suspect in leukemia-like disease

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Successful expression of human factor IX following repeat administration of adenoviral vector in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2802%2900044-8

7 January 2021

10.1016/S1525-0016(02)00044-8

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017